Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript

Kyverna Therapeutics, Inc. ( KYTX ) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials September 24, 2026 8:00 AM EDT Company Participants Jessica Serra - Head of Investor Relations Warner Biddle - CEO & Director Naji Gehchan - Chief Medical & Development Officer Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Avraham Novick - Morgan Stanley, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Mitchell Kapoor - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Thanks. Good morning, and welcome to the Kyverna Therapeutics Conference Call. [Operator Instructions] Please note, this call is being recorded. I would now like to introduce Jessica Serra, Head of Investor Relations. Jessica Serra Head of Investor Relations Today's conference call will cover the positive top line 1-year data from our KYSA-8 Registrational Trial of mivocabtagene autoleucel or Miv-cel, formerly referred to as KYV-101 in Stiff-Person syndrome as well as top line longer-term follow-up data from our KYSA-6 Phase II trial in generalized myasthenia gravis. I'd like to remind everyone that we will be making forward-looking statements during today's call. These statements reflect our current expectations and beliefs and are subject to risks and uncertainties that may cause actual results to differ materially. Please review our safe harbor statement in our press release and presentation materials and risk factors included in our SEC filings for additional information. Joining us today are Warner Biddle, our Chief Executive Officer; and Naji Gehchan, our Chief Medical and Development Officer. Warner will start with brief remarks, followed by Naji, who will cover our data for Stiff-Person syndrome, or SPS, and generalized myasthenia gravis or gMG, after Warner will close on our commercial opportunity in Stiff-Person syndrome. Following our prepared remarks, Greg Martini, our Chief Financial Officer, will join